Head to Head

ABCL vs ALNY: which is the better buy in 2026?

AbCellera Biologics Inc.

NASDAQ:ABCL

89/100 Compass
True NorthAccumulate$3.2B

Antibody discovery factory pivoting to owning the drugs it finds, with two Phase 1/2 readouts that could re-rate the whole thesis.

Full ABCL analysis

Alnylam Pharmaceuticals

NASDAQ:ALNY

89/100 Compass
True NorthAccumulate$30.0B

RNAi's first profitable platform company is trading near its 52-week low while its pipeline has never been broader or more valuable.

Full ALNY analysis

Factor by factor

FactorABCLALNY
Revenue Growth9883
Profitability951
Valuation6937
Momentum9022
Theme Purity5899
Moat5049
Catalysts6399
Market Position4852

Get head-to-heads like this, free

Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.

Free forever. Unsubscribe anytime. We never share your email.

Frequently asked questions

Is ABCL or ALNY the better buy in 2026?

ABCL and ALNY are neck and neck at 89/100 on the Compass right now. The better fit depends on which factors matter most to you.

How does Alexandria compare ABCL and ALNY?

Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.

Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.